Benznidazole Biotransformation and Multiple Targets in Trypanosoma cruzi Revealed by Metabolomics

PLoS Neglected Tropical Diseases

Volumn 8, Issue 5, 2014, Pages

  Trochine, Andrea ^a   Creek, Darren J ^b,c   Faral Tello, Paula ^a   Barrett, Michael P ^b   Robello, Carlos ^a,d  

^a INSTITUT PASTEUR DE MONTEVIDEO   (Uruguay)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d UNIVERSIDAD DE LA REPÚBLICA   (Uruguay)

Author keywords

[No Author keywords available]

Indexed keywords

BENZNIDAZOLE; CADAVERINE; CYSTEINE; DRUG METABOLITE; GAMMA GLUTAMYLCYSTEINE; GLUTATHIONE; GLYOXAL; HOMOCYSTEINE; NIFURTIMOX; OVOTHIOL A; PUTRESCINE; SPERMIDINE; TRYPANOTHIONE; NITROIMIDAZOLE DERIVATIVE;

ARTICLE; BIOTRANSFORMATION; CELL DISRUPTION; CELL VIABILITY; CHAGAS DISEASE; CONTROLLED STUDY; EPIMASTIGOTE; HYDROPHILIC INTERACTION CHROMATOGRAPHY; MASS SPECTROMETRY; METABOLOME; METABOLOMICS; NONHUMAN; PRINCIPAL COMPONENT ANALYSIS; TRYPANOSOMA CRUZI; DRUG EFFECTS; METABOLISM;

BIOTRANSFORMATION; GLUTATHIONE; MASS SPECTROMETRY; METABOLIC NETWORKS AND PATHWAYS; METABOLOME; METABOLOMICS; NITROIMIDAZOLES; TRYPANOSOMA CRUZI;

EID: 84901795109     PISSN: 19352727     EISSN: 19352735     Source Type: Journal    
DOI: 10.1371/journal.pntd.0002844     Document Type: Article

References (69)

1. Schofield CJ, Jannin J, Salvatella R, (2006) The future of Chagas disease control. Trends Parasitol 22: 583-588.
2. Remme JHF, Feenstra P, Lever PR, Medici AC, Morel CM, et al. (2006) Tropical Diseases Targeted for Elimination: Chagas Disease, Lymphatic Filariasis, Onchocerciasis, and Leprosy. In: Jamison DT, Breman JG, Measham AR, Alleyne G, Claeson M et al., editors. Disease Control Priorities in Developing Countries 2nd ed. Washington (DC): World Bank.
3. Rassi A Jr, Rassi A, Marin-Neto JA, (2010) Chagas disease. Lancet 375: 1388-1402.
4. Wilkinson SR, Bot C, Kelly JM, Hall BS, (2011) Trypanocidal activity of nitroaromatic prodrugs: current treatments and future perspectives. Curr Top Med Chem 11: 2072-2084.
5. Urbina JA, (2010) Specific chemotherapy of Chagas disease: relevance, current limitations and new approaches. Acta Trop 115: 55-68.
6. Marin-Neto JA, Rassi A Jr, Avezum A Jr, Mattos AC, Rassi A, et al. (2009) The BENEFIT trial: testing the hypothesis that trypanocidal therapy is beneficial for patients with chronic Chagas heart disease. Mem Inst Oswaldo Cruz 104 Suppl 1: 319-324.
7. Priotto G, Kasparian S, Mutombo W, Ngouama D, Ghorashian S, et al. (2009) Nifurtimox-eflornithine combination therapy for second-stage African Trypanosoma brucei gambiense trypanosomiasis: a multicentre, randomised, phase III, non-inferiority trial. Lancet 374: 56-64.
8. Torreele E, Bourdin Trunz B, Tweats D, Kaiser M, Brun R, et al. (2010) Fexinidazole-a new oral nitroimidazole drug candidate entering clinical development for the treatment of sleeping sickness. PLoS Negl Trop Dis 4: e923.
9. Diacon AH, Dawson R, du Bois J, Narunsky K, Venter A, et al. (2012) Phase II dose-ranging trial of the early bactericidal activity of PA-824. Antimicrob Agents Chemother 56: 3027-3031.
10. Upcroft JA, Campbell RW, Benakli K, Upcroft P, Vanelle P, (1999) Efficacy of new 5-nitroimidazoles against metronidazole-susceptible and-resistant Giardia, Trichomonas, and Entamoeba spp. Antimicrob Agents Chemother 43: 73-76.
11. Singh R, Manjunatha U, Boshoff HI, Ha YH, Niyomrattanakit P, et al. (2008) PA-824 kills nonreplicating Mycobacterium tuberculosis by intracellular NO release. Science 322: 1392-1395.
12. Diaz de Toranzo EG, Castro JA, Franke de Cazzulo BM, Cazzulo JJ, (1988) Interaction of benznidazole reactive metabolites with nuclear and kinetoplastic DNA, proteins and lipids from Trypanosoma cruzi. Experientia 44: 880-881.
13. Maya JD, Cassels BK, Iturriaga-Vasquez P, Ferreira J, Faundez M, et al. (2007) Mode of action of natural and synthetic drugs against Trypanosoma cruzi and their interaction with the mammalian host. Comp Biochem Physiol A Mol Integr Physiol 146: 601-620.
14. Wilkinson SR, Taylor MC, Horn D, Kelly JM, Cheeseman I, (2008) A mechanism for cross-resistance to nifurtimox and benznidazole in trypanosomes. Proc Natl Acad Sci U S A 105: 5022-5027.
15. Hall BS, Bot C, Wilkinson SR, (2011) Nifurtimox activation by trypanosomal type I nitroreductases generates cytotoxic nitrile metabolites. J Biol Chem 286: 13088-13095.
16. Wyllie S, Patterson S, Fairlamb AH, (2013) Assessing the Essentiality of Leishmania donovani Nitroreductase and Its Role in Nitro Drug Activation. Antimicrob Agents Chemother 57: 901-906.
17. Hall BS, Wilkinson SR, (2012) Activation of benznidazole by trypanosomal type I nitroreductases results in glyoxal formation. Antimicrob Agents Chemother 56: 115-123.
18. Creek DJ, Jankevics A, Breitling R, Watson DG, Barrett MP, et al. (2011) Toward global metabolomics analysis with hydrophilic interaction liquid chromatography-mass spectrometry: improved metabolite identification by retention time prediction. Anal Chem 83: 8703-8710.
19. Contreras VT, Araujo-Jorge TC, Bonaldo MC, Thomaz N, Barbosa HS, et al. (1988) Biological aspects of the Dm 28c clone of Trypanosoma cruzi after metacyclogenesis in chemically defined media. Mem Inst Oswaldo Cruz 83: 123-133.
20. Camargo EP, (1964) Growth and Differentiation in Trypanosoma Cruzi. I. Origin of Metacyclic Trypanosomes in Liquid Media. Rev Inst Med Trop Sao Paulo 6: 93-100.
21. t'Kindt R, Jankevics A, Scheltema RA, Zheng L, Watson DG, et al. (2010) Towards an unbiased metabolic profiling of protozoan parasites: optimisation of a Leishmania sampling protocol for HILIC-orbitrap analysis. Anal Bioanal Chem 398: 2059-2069.
22. Scheltema RA, Jankevics A, Jansen RC, Swertz MA, Breitling R, (2011) PeakML/mzMatch: a file format, Java library, R library, and tool-chain for mass spectrometry data analysis. Anal Chem 83: 2786-2793.
23. Creek DJ, Jankevics A, Burgess KE, Breitling R, Barrett MP, (2012) IDEOM: an Excel interface for analysis of LC-MS-based metabolomics data. Bioinformatics 28: 1048-1049.
24. Smith CA, Want EJ, O'Maille G, Abagyan R, Siuzdak G, (2006) XCMS: processing mass spectrometry data for metabolite profiling using nonlinear peak alignment, matching, and identification. Anal Chem 78: 779-787.
25. Varghese AJ, (1983) Glutathione conjugates of misonidazole. Biochem Biophys Res Commun 112: 1013-1020.
26. Raleigh JA, Koch CJ, (1990) Importance of thiols in the reductive binding of 2-nitroimidazoles to macromolecules. Biochem Pharmacol 40: 2457-2464.
27. Knox RJ, Knight RC, Edwards DI, (1983) Studies on the action of nitroimidazole drugs. The products of nitroimidazole reduction. Biochem Pharmacol 32: 2149-2156.
28. Kanehisa M, Goto S, Furumichi M, Tanabe M, Hirakawa M, (2010) KEGG for representation and analysis of molecular networks involving diseases and drugs. Nucleic Acids Res 38: D355-360.
29. Sud M, Fahy E, Cotter D, Brown A, Dennis EA, et al. (2007) LMSD: LIPID MAPS structure database. Nucleic Acids Res 35: D527-532.
30. Barrett MP, Bakker BM, Breitling R, (2010) Metabolomic systems biology of trypanosomes. Parasitology 137: 1285-1290.
31. Hunter KJ, Le Quesne SA, Fairlamb AH, (1994) Identification and biosynthesis of N1,N9-bis(glutathionyl)aminopropylcadaverine (homotrypanothione) in Trypanosoma cruzi. Eur J Biochem 226: 1019-1027.
32. Panicucci R, McClelland RA, (1989) 4,5-Dihydro-4,5-dihydroxyimidazoles as products of the reduction of 2-nitroimidazoles. HPLC assay and demonstration of equilibrium transfer of glyoxal to guanine. Can J Chem 67: 2128-2135.
33. Li F, Lu J, Ma X, (2011) Profiling the reactive metabolites of xenobiotics using metabolomic technologies. Chem Res Toxicol 24: 744-751.
34. Vincent IM, Creek DJ, Burgess K, Woods DJ, Burchmore RJ, et al. (2012) Untargeted metabolomics reveals a lack of synergy between nifurtimox and eflornithine against Trypanosoma brucei. PLoS Negl Trop Dis 6: e1618.
35. Silva AM, Cordeiro-da-Silva A, Coombs GH, (2011) Metabolic variation during development in culture of Leishmania donovani promastigotes. PLoS Negl Trop Dis 5: e1451.
36. t'Kindt R, Scheltema RA, Jankevics A, Brunker K, Rijal S, et al. (2010) Metabolomics to unveil and understand phenotypic diversity between pathogen populations. PLoS Negl Trop Dis 4: e904.
37. Kamleh A, Barrett MP, Wildridge D, Burchmore RJ, Scheltema RA, et al. (2008) Metabolomic profiling using Orbitrap Fourier transform mass spectrometry with hydrophilic interaction chromatography: a method with wide applicability to analysis of biomolecules. Rapid Commun Mass Spectrom 22: 1912-1918.
38. Creek DJ, Nijagal B, Kim DH, Rojas F, Matthews KR, et al. (2013) Metabolomics Guides Rational Development of a Simplified Cell Culture Medium for Drug Screening against Trypanosoma brucei. Antimicrob Agents Chemother 57: 2768-2779.
39. Zhang T, Creek DJ, Barrett MP, Blackburn G, Watson DG, (2012) Evaluation of coupling reversed phase, aqueous normal phase, and hydrophilic interaction liquid chromatography with Orbitrap mass spectrometry for metabolomic studies of human urine. Anal Chem 84: 1994-2001.
40. de Souza W, Sant'Anna C, Cunha-e-Silva NL, (2009) Electron microscopy and cytochemistry analysis of the endocytic pathway of pathogenic protozoa. Prog Histochem Cytochem 44: 67-124.
41. Polak A, Richle R, (1978) Mode of action of the 2-nitroimidazole derivative benznidazole. Ann Trop Med Parasitol 72: 45-54.
42. Goijman SG, Stoppani AO, (1985) Effects of nitroheterocyclic drugs on macromolecule synthesis and degradation in Trypanosoma cruzi. Biochem Pharmacol 34: 1331-1336.
43. Goijman SG, Frasch AC, Stoppani AO, (1985) Damage of Trypanosoma cruzi deoxyribonucleic acid by nitroheterocyclic drugs. Biochem Pharmacol 34: 1457-1461.
44. Rajao MA, Furtado C, Alves CL, Passos-Silva DG, de Moura MB, et al. (2013) Unveiling Benznidazole's mechanism of action through overexpression of DNA repair proteins in Trypanosoma cruzi. Environ Mol Mutagen 55 (4) (): 309-21.
45. Kasai H, Iwamoto-Tanaka N, Fukada S, (1998) DNA modifications by the mutagen glyoxal: adduction to G and C, deamination of C and GC and GA cross-linking. Carcinogenesis 19: 1459-1465.
46. Zeng J, Davies MJ, (2005) Evidence for the formation of adducts and S-(carboxymethyl)cysteine on reaction of alpha-dicarbonyl compounds with thiol groups on amino acids, peptides, and proteins. Chem Res Toxicol 18: 1232-1241.
47. Greig N, Wyllie S, Vickers TJ, Fairlamb AH, (2006) Trypanothione-dependent glyoxalase I in Trypanosoma cruzi. Biochem J 400: 217-223.
48. Buckner FS, (2008) Sterol 14-demethylase inhibitors for Trypanosoma cruzi infections. Adv Exp Med Biol 625: 61-80.
49. Diniz Lde F, Urbina JA, de Andrade IM, Mazzeti AL, Martins TA, et al. (2013) Benznidazole and posaconazole in experimental Chagas disease: positive interaction in concomitant and sequential treatments. PLoS Negl Trop Dis 7: e2367.
50. Raleigh JA, Liu SF, (1984) Reductive fragmentation of 2-nitroimidazoles: amines and aldehydes. Int J Radiat Oncol Biol Phys 10: 1337-1340.
51. Repetto Y, Opazo E, Maya JD, Agosin M, Morello A, (1996) Glutathione and trypanothione in several strains of Trypanosoma cruzi: effect of drugs. Comp Biochem Physiol B Biochem Mol Biol 115: 281-285.
52. Maya JD, Repetto Y, Agosin M, Ojeda JM, Tellez R, et al. (1997) Effects of nifurtimox and benznidazole upon glutathione and trypanothione content in epimastigote, trypomastigote and amastigote forms of Trypanosoma cruzi. Mol Biochem Parasitol 86: 101-106.
53. Maya JD, Bollo S, Nunez-Vergara LJ, Squella JA, Repetto Y, et al. (2003) Trypanosoma cruzi: effect and mode of action of nitroimidazole and nitrofuran derivatives. Biochem Pharmacol 65: 999-1006.
54. Faundez M, Lopez-Munoz R, Torres G, Morello A, Ferreira J, et al. (2008) Buthionine sulfoximine has anti-Trypanosoma cruzi activity in a murine model of acute Chagas' disease and enhances the efficacy of nifurtimox. Antimicrob Agents Chemother 52: 1837-1839.
55. Leitsch D, Kolarich D, Wilson IB, Altmann F, Duchene M, (2007) Nitroimidazole action in Entamoeba histolytica: a central role for thioredoxin reductase. PLoS Biol 5: e211.
56. Leitsch D, Kolarich D, Binder M, Stadlmann J, Altmann F, et al. (2009) Trichomonas vaginalis: metronidazole and other nitroimidazole drugs are reduced by the flavin enzyme thioredoxin reductase and disrupt the cellular redox system. Implications for nitroimidazole toxicity and resistance. Mol Microbiol 72: 518-536.
57. Maya JD, Rodriguez A, Pino L, Pabon A, Ferreira J, et al. (2004) Effects of buthionine sulfoximine nifurtimox and benznidazole upon trypanothione and metallothionein proteins in Trypanosoma cruzi. Biol Res 37: 61-69.
58. Pineyro MD, Parodi-Talice A, Arcari T, Robello C, (2008) Peroxiredoxins from Trypanosoma cruzi: virulence factors and drug targets for treatment of Chagas disease? Gene 408: 45-50.
59. Walton MI, Workman P, (1987) Nitroimidazole bioreductive metabolism. Quantitation and characterisation of mouse tissue benznidazole nitroreductases in vivo and in vitro. Biochem Pharmacol 36: 887-896.
60. Portal P, Villamil SF, Alonso GD, De Vas MG, Flawia MM, et al. (2008) Multiple NADPH-cytochrome P450 reductases from Trypanosoma cruzi suggested role on drug resistance. Mol Biochem Parasitol 160: 42-51.
61. Murta SM, Krieger MA, Montenegro LR, Campos FF, Probst CM, et al. (2006) Deletion of copies of the gene encoding old yellow enzyme (TcOYE), a NAD(P)H flavin oxidoreductase, associates with in vitro-induced benznidazole resistance in Trypanosoma cruzi. Mol Biochem Parasitol 146: 151-162.
62. Kubata BK, Kabututu Z, Nozaki T, Munday CJ, Fukuzumi S, et al. (2002) A key role for old yellow enzyme in the metabolism of drugs by Trypanosoma cruzi. J Exp Med 196: 1241-1251.
63. Brisse S, Dujardin JC, Tibayrenc M, (2000) Identification of six Trypanosoma cruzi lineages by sequence-characterised amplified region markers. Mol Biochem Parasitol 111: 95-105.
64. Andrade SG, Magalhaes JB, Pontes AL, (1985) Evaluation of chemotherapy with benznidazole and nifurtimox in mice infected with Trypanosoma cruzi strains of different types. Bull World Health Organ 63: 721-726.
65. Revollo S, Oury B, Laurent JP, Barnabe C, Quesney V, et al. (1998) Trypanosoma cruzi: impact of clonal evolution of the parasite on its biological and medical properties. Exp Parasitol 89: 30-39.
66. Yamada T, Letunic I, Okuda S, Kanehisa M, Bork P, (2011) iPath2.0: interactive pathway explorer. Nucleic Acids Res 39: W412-415.
67. Guha R, (2007) Chemical informatics functionality in R. Journal of Statistical Software 18: 16.
68. Xia J, Mandal R, Sinelnikov IV, Broadhurst D, Wishart DS, (2012) MetaboAnalyst 2.0-a comprehensive server for metabolomic data analysis. Nucleic Acids Res 40: W127-133.
69. Xia J, Psychogios N, Young N, Wishart DS, (2009) MetaboAnalyst: a web server for metabolomic data analysis and interpretation. Nucleic Acids Res 37: W652-660.